AUTHORS
Guillaume Lefèvre, MD, PhD, Guillaume Moulis, MD, PhD2, Matthieu Groh, MD, MSc3, Irène Machelart4, Nicolas Limal5, Noémie Abisror6, Nabil Belfeki7, Bernard Bonnotte, MD, PhD8, Antoine Dossier9, Yasmine El Maamar10, Emmanuel Ledoult11, Noémie Le Gouellec12, Sarah Melboucy13, Antoine Néel, MD, PhD14, Mathieu Puyade15, Julien Rohmer, MD16, Nicolas Schleinitz17, Louis Terriou, MD18, Laurine Cadart19, Cécile Lecocq20, Japhete Elenga-Koanga21, Séverine Bleuse22, Sarah Khelil23, Kewin Panel24, Florence E. Roufosse25, Jean-Emmanuel Kahn, MD26
AFFILIATIONS
1 CHU Lille, Reference Center for Hypereosinophilic Syndromes (CEREO), Lille, France
2 CHU Toulouse, Université Toulouse III Paul Sabatier, Toulouse, France
3 Foch Hospital, Reference center for Hypereosinophilic Syndromes (CEREO), Suresnes, France
4 CHU Bordeaux, Bordeaux, France
5 Hôpital Henri Mondor, APHP, Université Paris-Est Créteil,, Créteil, France
6 Hôpital Saint Antoine, APHP, Sorbonne Université, Paris, France
7 CHU Dijon, Université de Bourgogne, Dijon, France
8 CHU Dijon, Université de Bourgogne, Dijon, France
9 Hôpital Bichat, Université Paris Cité, APHP, Paris, France
10 CH Arras, Arras, France
11 CHU Lille, Reference Center for Hypereosinophilic Syndromes (CEREO), Lille, France
12 CH Valenciennes, Valenciennes, France
13 CH Saint-Quentin, Saint-Quentin, France
14 CHU Nantes, Université de Nantes, Nantes, France
15 CHU Poitiers, Faculté de Médecine et de Pharmacie de Poitiers, Poitiers, France
16 Foch Hospital, Reference center for Hypereosinophilic Syndromes (CEREO), Suresnes, France
17 Hôpital de la Timone, AP-HM, Aix-Marseille Université, Marseille, France
18 CHU Lille, Reference Center for Hypereosinophilic Syndromes (CEREO), Lille, France
19 CHU Lille, Lille, France
20 CHU Lille, Lille, France
21 CHU Lille, Lille, France
22 CHU Lille, Reference Center for Hypereosinophilic Syndromes (CEREO), Lille, France
23 Foch Hospital, Reference center for Hypereosinophilic Syndromes (CEREO), Suresnes, France
24 Foch Hospital, Reference center for Hypereosinophilic Syndromes (CEREO), Suresnes, France
25 Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Bruxelles, Belgium
26 Hôpital Ambroise Paré, APHP, Reference center for Hypereosinophilic Syndromes (CEREO), Boulogne-Billancourt, France
ABSTRACT
Introduction. Although IL-5/IL-5R-targeting biologics demonstrated efficacy in Hypereosinophilic syndromes (HES) in 6-month randomized trials (Roufosse et al. JACI 2020; Ogbogu et al. Nat Medicine 2026), real-world long-term data on flare prevention and glucocorticoid (GC)-sparing effects remain limited.
Methods. COHESion is a prospective European multicenter cohort of adults and children with eosinophilic disorders, initiated in 2019, with annual follow-up (NCT04018118, Lefèvre et al. Allergy 2025). In the present study, we selected patients with idiopathic HES (I-HES) treated with biologics either before or after enrollment, either at the HES-approved dose (mepolizumab 300 mg every 4 weeks or benralizumab 30 mg every 4 weeks) or at lower doses (e.g., mepolizumab 100 mg every 4 weeks or benralizumab 30 mg every 8 weeks). The primary objective was to assess treatment-induced changes in the annualized flare rate and cumulative annual GC dose among patients initiating biologics at the HES-approved dose after enrollment in the cohort, with at least 10 months of follow-up. The second objective was to assess the proportion of patients achieving ≤5 mg prednisolone-equivalent/day and/or complete GC withdrawal among all patients treated with the approved dose (including those who initiated the biologic before cohort enrollment). The third objective was to assess the proportion of patients who required biologic dose escalation to the HES-approved dose, among those initially treated with lower doses. Continuous variables are presented as medians [IQR] and were compared using non-parametric tests; categorical variables were compared using the chi-square test.
Results. Among 1,052 enrolled patients, data was complete for 786, including 380 with I-HES, 149 of which received anti-IL-5/IL-5R therapy. Patients previously enrolled in trials or compassionate-use programs (n=13), treated exclusively for asthma and/or nasal polyps (n=12), or without any post-initiation visit (n=23) were excluded. Among the 101 patients selected in this analysis, 69 initiated treatment at the HES-approved dose of anti-IL5/IL-5R, including 35 who started before enrollment in the cohort, and 34 who started afterwards. Thirty-two additional patients initiated treatment at a lower dose.
Thirty-four patients treated at the approved dose were eligible to the primary analysis (mepolizumab, n=28, or benralizumab, n=6). Median follow-up from biologic initiation to the first post-initiation evaluation was 11.5 [10-14] months and the total median follow-up after biologic initiation was 30 [2-35] months. The proportion of patients with ≥1 HES flare during the preceding 12 months decreased from 65% (22/34) at baseline to 19% (6/32) after 1 year of treatment (p<0.001) and 12.5% (4/32) at the last visit (p<0.001). Background GC use decreased from 84% (29/34) of patients at baseline, to 41% (14/34) at the first follow-up (p<0.001) and 18% (6/34) at the last visit (p<0.001). Median annual cumulative GC dose decreased from 1.7 [0.8–2.9] g at baseline to 0 [0–1.1] g at the first follow-up (p<0.001) and remained at 0 [0–0] g at the last visit (p<0.001).
Sixty-nine patients initiated treatment at the approved dose and were selected for the second objective (mepolizumab, n=60, or benralizumab, n=9). One patient discontinued both biologics because of severe oligoarthritis. After a median follow-up of 29 [16–36] months after biologic initiation, 78% (54/69) achieved GC tapering to ≤5 mg/day and 74% (51/69) completely discontinued GC. Among patients followed for ≥24 months (n=42; median 34.5 [31–43] months), 100% achieved a GC dose ≤5 mg/day and 36/42 (86%) discontinued GC.
Thirty-two patients initially received their biologic at a dose lower than that approved for HES. Nine (28%) required dose escalation and/or treatment switching because of insufficient efficacy. One patient discontinued mepolizumab because of severe oligoarthritis but subsequently tolerated benralizumab.
Conclusions. In this real-world multi-center cohort, use of anti-IL-5/IL-5R biologics at HES-approved dosing regimens enabled sustained reductions in HES flares together with marked GC-sparing effects. In contrast, treatment failure was observed in a subset of patients receiving lower doses, supporting the use of HES-approved dosing. A minority of patients continued to receive GCs, underscoring the need to optimize GC management after anti-IL-5/IL-5R initiation, and to define optimal long-term biologic management.
DISCLOSURES
Guillaume Lefèvre, MD, PhD: GSK - Honoraria; AstraZeneca - Honoraria; GSK - Research Funding; AstraZeneca - Research Funding; AstraZeneca - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony)